The overall percentage of tumors with measurable PD-L1 tumor expression (≥1%) using LDTs (63%) was similar to that using the 22C3 (61%) and the 28–8 (61%); however, the proportion with PD-L1 ≥50% was much lower (23% vs. 33% and 32%, respectively), suggesting that the LDTs as a group could be less sensitive IHC assays. This evidence concerns the gene CD274 and neoplasm.